Pilot study on combination of azacitidine and low-dose cytarabine for patients with refractory anemia with excess blast

Annals of Hematology

Volumn 91, Issue 3, 2012, Pages 367-373

  Moon, Joon Ho ^a   Lee, Soo Jung ^a   Lee, Yoo Jin ^a   Kang, Byung Woog ^a   Chae, Yee Soo ^a   Kim, Jong Gwang ^a   Suh, Jang Soo ^a   Sohn, Sang Kyun ^a  

^a Kyungpook National University Hospital   (South Korea)

Author keywords

Azacitidine; Cytarabine; Epigenetic therapy; Myelodysplastic syndrome; Refractory anemia with excess blast

Indexed keywords

AZACITIDINE; CIPROFLOXACIN; CYTARABINE; FLUCONAZOLE; HEMOGLOBIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; BONE MARROW EXAMINATION; CLINICAL ARTICLE; CLONAL EVOLUTION; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DISEASE COURSE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FEMALE; HUMAN; INFECTION; KARYOTYPE; LEUKOPENIA; LOW DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PILOT STUDY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REFRACTORY ANEMIA WITH EXCESS BLASTS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; CYTARABINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; TREATMENT OUTCOME;

EID: 84857372718     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-011-1321-1     Document Type: Article

References (22)

1. EM Sloand 2008 Myelodysplastic syndromes: introduction Semin Hematol 45 1 1 2 18179962 10.1053/j.seminhematol.2007.11.008
2. P Valent HP Horny JM Bennett C Fonatsch U Germing P Greenberg T Haferlach D Haase HJ Kolb O Krieger M Loken A van de Loosdrecht K Ogata A Orfao M Pfeilstocker B Ruter WR Sperr R Stauder DA Wells 2007 Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference Leuk Res 31 6 727 736 17257673 10.1016/j.leukres.2006.11.009 (Pubitemid 46855901)
3. P Fenaux GJ Mufti E Hellstrom-Lindberg V Santini C Finelli A Giagounidis R Schoch N Gattermann G Sanz A List SD Gore JF Seymour JM Bennett J Byrd J Backstrom L Zimmerman D McKenzie C Beach LR Silverman 2009 Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study Lancet Oncol 10 3 223 232 19230772 10.1016/S1470-2045(09)70003-8 1:CAS:528:DC%2BD1MXisFWjsbc%3D
4. LR Silverman EP Demakos BL Peterson AB Kornblith JC Holland R Odchimar-Reissig RM Stone D Nelson BL Powell CM DeCastro J Ellerton RA Larson CA Schiffer JF Holland 2002 Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B J Clin Oncol 20 10 2429 2440 12011120 10.1200/JCO.2002.04.117 1:CAS:528:DC%2BD38XksFakur8%3D (Pubitemid 34525728)
5. H Kantarjian JP Issa CS Rosenfeld JM Bennett M Albitar J DiPersio V Klimek J Slack C de Castro F Ravandi R Helmer 3rd L Shen SD Nimer R Leavitt A Raza H Saba 2006 Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study Cancer 106 8 1794 1803 16532500 10.1002/cncr.21792 1:CAS:528:DC%2BD28XksFCrsrk%3D
6. HM Kantarjian S O'Brien X Huang G Garcia-Manero F Ravandi J Cortes J Shan J Davisson CE Bueso-Ramos JP Issa 2007 Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience Cancer 109 6 1133 1137 17315156 10.1002/cncr.22508 1:CAS:528:DC%2BD2sXkt1WmtL4%3D (Pubitemid 46435392)
7. A Kuendgen M Lubbert 2008 Current status of epigenetic treatment in myelodysplastic syndromes Ann Hematol 87 8 601 611 18392623 10.1007/s00277-008- 0477-9 1:CAS:528:DC%2BD1cXnvVOnurw%3D
8. JH Moon SN Kim BW Kang YS Chae JG Kim JH Baek JH Park MK Song JS Chung JH Won SM Lee YD Joo YK Kim HJ Kim DY Jo SK Sohn 2010 Predictive value of pretreatment risk group and baseline LDH levels in MDS patients receiving azacitidine treatment Ann Hematol 89 7 681 689 20237926 10.1007/s00277-010-0921- 5 1:CAS:528:DC%2BC3cXmtlyhsLk%3D
9. X Yang F Lay H Han PA Jones 2010 Targeting DNA methylation for epigenetic therapy Trends Pharmacol Sci 31 11 536 546 20846732 10.1016/j.tips.2010.08.001
10. BD Cheson PL Greenberg JM Bennett B Lowenberg PW Wijermans SD Nimer A Pinto M Beran TM de Witte RM Stone M Mittelman GF Sanz SD Gore CA Schiffer H Kantarjian 2006 Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia Blood 108 2 419 425 16609072 10.1182/blood-2005-10-4149 1:CAS:528:DC%2BD28XntFehtrk%3D (Pubitemid 44061337)
11. SA Johnson 2001 Nucleoside analogues in the treatment of haematological malignancies Expert Opin Pharmacother 2 6 929 943 11585009 10.1517/14656566.2.6. 929 1:CAS:528:DC%2BD3MXkvVKmtbc%3D (Pubitemid 32750349)
12. D Sampath VA Rao W Plunkett 2003 Mechanisms of apoptosis induction by nucleoside analogs Oncogene 22 56 9063 9074 14663485 10.1038/sj.onc.1207229 1:CAS:528:DC%2BD3sXpsFOmsrY%3D (Pubitemid 38121707)
13. T Qin EM Youssef J Jelinek R Chen AS Yang G Garcia-Manero JP Issa 2007 Effect of cytarabine and decitabine in combination in human leukemic cell lines Clin Cancer Res 13 14 4225 4232 17634552 10.1158/1078-0432.CCR-06-2762 1:CAS:528:DC%2BD2sXnvVChsb0%3D (Pubitemid 47105987)
14. T Colombo C Rossi M D'Incalci 1986 Antagonism of 5-aza-2′- deoxycytidine antileukemic activity by concomitant treatment with cytarabine Cancer Treat Rep 70 12 1451 1453 2431776 1:CAS:528:DyaL2sXht1emtw%3D%3D (Pubitemid 17005131)
15. T Qin J Jelinek J Si J Shu JP Issa 2009 Mechanisms of resistance to 5-aza-2′-deoxycytidine in human cancer cell lines Blood 113 3 659 667 18931345 10.1182/blood-2008-02-140038 1:CAS:528:DC%2BD1MXht1Wnsb8%3D
16. G Borthakur X Huang H Kantarjian S Faderl F Ravandi A Ferrajoli R Torma G Morris D Berry JP Issa 2010 Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes Leuk Lymphoma 51 1 73 78 20017599 10.3109/ 10428190903318329 1:CAS:528:DC%2BC3cXitlyktg%3D%3D
17. Kim DY, Lee JH, Park YH, Lee JH, Kim SD, Choi Y, Lee SB, Lee KH, Ahn SY, Lee YS, Seol M, Kang YA, Jeon M, Jung AR, Lee YJ, Lee KH (2011) Feasibility of hypomethylating agents followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome. Bone Marrow Transplant. doi: 10.1038/bmt.2011.86
18. M Lubbert P Wijermans R Kunzmann G Verhoef A Bosly C Ravoet M Andre A Ferrant 2001 Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine Br J Haematol 114 2 349 357 11529854 10.1046/j.1365-2141.2001.02933.x 1:CAS:528:DC%2BD3MXmsVyhu7w%3D (Pubitemid 32762234)
19. H Kantarjian Y Oki G Garcia-Manero X Huang S O'Brien J Cortes S Faderl C Bueso-Ramos F Ravandi Z Estrov A Ferrajoli W Wierda J Shan J Davis F Giles HI Saba JP Issa 2007 Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia Blood 109 1 52 57 16882708 10.1182/blood-2006-05-021162 1:CAS:528:DC%2BD2sXivVyrt7c%3D (Pubitemid 46053042)
20. DP Steensma MR Baer JL Slack R Buckstein LA Godley G Garcia-Manero M Albitar JS Larsen S Arora MT Cullen H Kantarjian 2009 Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial J Clin Oncol 27 23 3842 3848 19528372 10.1200/JCO.2008.19.6550 1:CAS:528:DC%2BD1MXhtFaitrrI
21. F Braulke J Schanz K Jung K Shirneshan K Schulte C Schuetze R Steffens L Trumper D Haase 2010 FISH analysis of circulating CD34+ cells as a new tool for genetic monitoring in MDS: verification of the method and application to 27 MDS patients Leuk Res 34 10 1296 1301 20226527 10.1016/j.leukres.2010.01.010 1:CAS:528:DC%2BC3cXhtV2itLbJ
22. HM Schmetzer B Poleck T Duell HH Gerhartz J Mittermuller 2000 Cytogenetic and Southern blot analysis to demonstrate clonality and to estimate prognosis in patients with myelodysplastic syndromes Ann Hematol 79 1 20 29 10663617 10.1007/s002770050004 1:STN:280:DC%2BD3c7ivFGgtQ%3D%3D (Pubitemid 30157746)